Belatacept + methylprednisolone + Anti-thymocyte Globulin (Rabbit) + Tacrolimus + Mycophenolate mofetil
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Simultaneous Kidney and Pancreas Transplantation
Conditions
Simultaneous Kidney and Pancreas Transplantation
Trial Timeline
Feb 1, 2013 → Aug 1, 2016
NCT ID
NCT01790594About Belatacept + methylprednisolone + Anti-thymocyte Globulin (Rabbit) + Tacrolimus + Mycophenolate mofetil
Belatacept + methylprednisolone + Anti-thymocyte Globulin (Rabbit) + Tacrolimus + Mycophenolate mofetil is a phase 2 stage product being developed by Bristol Myers Squibb for Simultaneous Kidney and Pancreas Transplantation. The current trial status is terminated. This product is registered under clinical trial identifier NCT01790594. Target conditions include Simultaneous Kidney and Pancreas Transplantation.
What happened to similar drugs?
1 of 1 similar drugs in Simultaneous Kidney and Pancreas Transplantation were approved
Approved (1) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01790594 | Phase 2 | Terminated |
Competing Products
1 competing product in Simultaneous Kidney and Pancreas Transplantation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Daclizumab | Roche | Approved | 43 |